New hit discovery service combines integrated DNA-Encoded Library screening, structural biology, biophysics, and X-ray crystallography
Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
Patnaik stressed early diagnosis, rapid treatment, and aggressive surveillance as the backbone of elimination efforts
Postal ballot also clears remuneration proposal and new ESOP 2026 scheme, strengthening the company’s leadership and talent retention strategy
New-generation cardiac ablation technology expands treatment options for atrial fibrillation patients, offering a non-thermal approach to improve safety and procedural efficiency
The decision was driven by results from the Phase III CAPItello-281 trial,
Samelisant will be the centerpiece of Suven’s scientific presence
The approval clears the company to market a generic version that is therapeutically equivalent to Retin-A Cream
Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
